NCT01589185 - Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2016

Study Completion Date

September 30, 2016

Conditions

Pneumonia Due to Staphylococcus Aureus

Interventions

DRUG

KBSA301

KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.

DRUG

Placebo

Placebo administered as a single intravenous infusion

Trial Locations (18)

Site 83, Jacksonville

Site 81, Oklahoma City

Site 80, Houston

Site 11, Brussels

Site 16, Liège

Site 41, Angers

Site 40, Angoulême

Site 32, Argenteuil

Site 34, Colombes

Site 36, Dijon

Site 35, La Roche-sur-Yon

Site 31, Limoges

Site 39, Lyon

Site 37, Nantes

Site 38, Orléans

Site 33, Tours

Site 51, Barcelona

Site 52, Barcelona